Yubo International Biotech Ltd (YBGJ)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Quarterly

-150K 0 150K 300K 450K Q1 '16: 0 Q2 '16: 0 Q3 '16: 0 Q4 '16: 0 Q1 '17: 0 Q2 '17: 0 Q3 '17: 0 Q4 '17: 0 Q1 '18: 0 Q2 '18: 0 Q3 '18: 0 Q4 '18: 0 Q1 '19: 0 Q2 '19: 0 Q3 '19: 0 Q4 '19: 0 Q1 '20: 0 Q2 '20: 0 Q3 '20: 0 Q4 '20: 0 Q3 '21: 98.3K Q4 '21: 332.3K Q1 '22: 15.2K Q2 '22: 8K Q3 '22: 14.6K Q4 '22: 66.5K Q1 '23: 156.6K Q2 '23: 1.4K Q3 '23: 428.5K Q4 '23: 22.3K Q1 '24: 3.5K Q2 '24: 0 Q3 '24: 0 Q4 '24: -18 Q1 '25: 0 Q2 '25: 0 Q3 '25: 0 Q4 '25: 12.4K Q1 '26: 0 Q2 '26: 0 Q1 '17 Q2 '18 Q3 '19 Q4 '20 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Gross Profit Quarterly

-300K 0 300K 600K 900K Q1 '20: 0 Q2 '20: 253.4K Q3 '20: 131.5K Q4 '20: 808.2K Q1 '21: 315.6K Q2 '21: 213K Q3 '21: 73.2K Q4 '21: 218.9K Q1 '22: 8.3K Q2 '22: 5.9K Q3 '22: 9.6K Q4 '22: 28.9K Q1 '23: 57.7K Q2 '23: 885 Q3 '23: 344.1K Q4 '23: 18.1K Q1 '24: 2.7K Q2 '24: 0 Q3 '24: 0 Q4 '24: -13 Q1 '25: 0 Q2 '25: 0 Q3 '25: 0 Q4 '25: 8.2K Q1 '26: 0 Q2 '26: 0 Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Operating Income Quarterly

-600K -400K -200K 0 200K 400K 600K Q2 '17: -23K Q3 '17: -22K Q4 '17: -22K Q2 '18: -21K Q3 '18: -12K Q4 '18: -7K Q1 '19: -8K Q2 '19: -8K Q3 '19: -8K Q4 '19: -8K Q1 '20: -4K Q1 '20: -140.9K Q2 '20: -7K Q2 '20: -32.1K Q3 '20: -21K Q3 '20: -304.5K Q4 '20: -25.5K Q4 '20: -281.7K Q1 '21: -438.6K Q2 '21: -370.1K Q3 '21: -346K Q4 '21: -388.2K Q1 '22: -578.9K Q2 '22: -491.5K Q3 '22: -238.3K Q4 '22: 103.5K Q1 '23: -316.5K Q2 '23: -367.3K Q3 '23: 6.4K Q4 '23: -517.3K Q1 '24: -409.4K Q2 '24: -470.4K Q3 '24: -532.8K Q4 '24: -357.3K Q1 '25: -467.3K Q2 '25: -249.7K Q3 '25: -310.1K Q4 '25: -285.5K Q1 '26: -289.3K Q2 '26: -238.9K Q3 '18 Q4 '19 Q3 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Net Income Quarterly

-750K -500K -250K 0 250K 500K 750K Q3 '17: -43K Q4 '17: -43K Q1 '18: -15K Q2 '18: -45K Q3 '18: -37K Q4 '18: -33K Q1 '19: -33K Q2 '19: -34K Q3 '19: -35K Q4 '19: -34K Q1 '20: -31K Q1 '20: -140.9K Q2 '20: -34K Q2 '20: -31.9K Q3 '20: 311K Q3 '20: -304.7K Q4 '20: -25.5K Q4 '20: -281.5K Q1 '21: -438.7K Q2 '21: -370K Q3 '21: -336.6K Q4 '21: -397.2K Q1 '22: -578.9K Q2 '22: -491.6K Q3 '22: -238.1K Q4 '22: 103.6K Q1 '23: -316.7K Q2 '23: -367.3K Q3 '23: 6.3K Q4 '23: -517.4K Q1 '24: -377.3K Q2 '24: -527.5K Q3 '24: -621.1K Q4 '24: -146.7K Q1 '25: -435.6K Q2 '25: -230.3K Q3 '25: -310.2K Q4 '25: -177K Q1 '26: -272.6K Q2 '26: -247.9K Q3 '18 Q4 '19 Q3 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Cost of Revenue Quarterly

-50K 0 50K 100K 150K Q1 '20: 0 Q2 '20: 23.3K Q3 '20: 63K Q4 '20: 74.5K Q1 '21: 146.7K Q2 '21: 138.5K Q3 '21: 25.1K Q4 '21: 113.4K Q1 '22: 6.9K Q2 '22: 2.1K Q3 '22: 5K Q4 '22: 37.6K Q1 '23: 98.9K Q2 '23: 545 Q3 '23: 84.4K Q4 '23: 4.2K Q1 '24: 827 Q2 '24: 0 Q3 '24: 0 Q4 '24: -5 Q1 '25: 0 Q2 '25: 0 Q3 '25: 0 Q4 '25: 4.2K Q1 '26: 0 Q2 '26: 0 Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Operating Cash Flow Quarterly

-1.1M -700K -350K 0 350K 700K 1.1M Q2 '17: -22K Q3 '17: -20K Q4 '17: -14K Q1 '18: 1K Q2 '18: -11K Q3 '18: -11K Q4 '18: -2K Q1 '19: -8K Q2 '19: -8K Q3 '19: -9K Q4 '19: -3K Q1 '20: -2K Q1 '20: -491.6K Q2 '20: -4K Q2 '20: 205.9K Q3 '20: -7K Q3 '20: -126.2K Q4 '20: 0 Q1 '21: -1M Q2 '21: 76.2K Q3 '21: -30.8K Q4 '21: -63.7K Q1 '22: 51K Q2 '22: -17.6K Q3 '22: 55.2K Q4 '22: -689.5K Q1 '23: -32.7K Q2 '23: -153K Q3 '23: 5.1K Q4 '23: -558.4K Q1 '24: -330.6K Q2 '24: -427.7K Q3 '24: 353.3K Q4 '24: -932.7K Q1 '25: -392K Q2 '25: -14K Q3 '25: -308K Q4 '25: -128.8K Q1 '26: -207.2K Q2 '26: -84.1K Q2 '18 Q3 '19 Q2 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Free Cash Flow Quarterly

-1.5M -1M -500K 0 500K 1M 1.5M Q1 '20: -539.9K Q2 '20: 200.8K Q3 '20: -136.3K Q1 '21: -1.5M Q2 '21: -59.1K Q3 '21: -71K Q4 '21: -81.7K Q1 '22: 41.4K Q2 '22: -27.2K Q3 '22: 55.2K Q4 '22: -689.5K Q1 '23: -32.7K Q2 '23: -153K Q3 '23: 5.1K Q1 '24: -349.5K Q1 '25: -398.2K Q1 '26: -207.2K Q2 '20 Q2 '21 Q1 '22 Q4 '22 Q3 '23 Q1 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 60M 120M 180M Q3 '19: 1.2M Q4 '19: 1.2M Q3 '20: 1.2M Q4 '20: 89.7M Q3 '23: 119.8M Q1 '24: 12M Q2 '24: 119.8M Q3 '24: 119.8M Q1 '25: 119.8M Q2 '25: 119.8M Q3 '25: 147.9M Q1 '26: 170.4M Q2 '26: 170.4M Q3 '19 Q3 '20 Q3 '23 Q2 '24 Q1 '25 Q3 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-0.24 -0.16 -0.08 0.00 0.08 0.16 0.24 Q3 '12: -0.07 Q4 '12: -0.08 Q1 '13: -0.09 Q2 '13: -0.09 Q3 '13: -0.09 Q4 '13: -0.08 Q1 '14: -0.08 Q2 '14: -0.08 Q3 '14: -0.08 Q4 '14: -0.09 Q1 '15: -0.09 Q2 '15: -0.10 Q3 '15: -0.11 Q4 '15: -0.11 Q1 '16: -0.11 Q2 '16: -0.11 Q3 '16: -0.11 Q4 '16: -0.12 Q1 '17: -0.20 Q2 '17: -0.21 Q3 '17: -0.21 Q4 '17: -0.21 Q1 '18: -0.12 Q2 '18: -0.12 Q3 '18: -0.12 Q4 '18: -0.11 Q1 '19: -0.13 Q2 '19: -0.12 Q3 '19: -0.12 Q4 '19: -0.12 Q1 '20: -0.11 Q2 '24: -0.09 Q3 '24: -0.10 Q4 '24: -0.02 Q1 '25: -0.02 Q2 '25: -0.02 Q3 '25: -0.01 Q4 '25: 0.00 Q1 '26: 0.00 Q2 '26: 0.00 Q3 '13 Q4 '14 Q1 '16 Q2 '17 Q3 '18 Q4 '19 Q1 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.